Related Experiment Video
Updated: Jul 23, 2025
Strategies for Assessing Autistic-Like Behaviors in Mice
Published on: September 20, 2024
Minocycline improves autism-related behaviors by modulating microglia polarization in a mouse model of autism
1Department of Military Cognitive Psychology, School of Psychology, Army Medical University, Chongqing 400038, China.
Abstract:
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with few pharmacological treatments. Minocycline, a tetracycline derivative that inhibits microglial activation, has been well-identified with anti-inflammatory properties and neuroprotective effects. A growing body of research suggests that ASD is associated with neuroinflammation, abnormal neurotransmitter levels, and neurogenesis. Thus, we hypothesized that minocycline could improve autism-related behaviors by inhibiting microglia activation and altering neuroinflammation. To verify our hypothesis, we used a mouse model of autism, BTBR T + Itpr3tf/J (BTBR). As expected, minocycline administration rescued the sociability and repetitive, stereotyped behaviors of BTBR mice while having no effect in C57BL/6J mice. We also found that minocycline improved neurogenesis and inhibited microglia activation in the hippocampus of BTBR mice. In addition, minocycline treatment inhibited Erk1/2 phosphorylation in the hippocampus of BTBR mice. Our findings show that minocycline administration alleviates ASD-like behaviors in BTBR mice and improves neurogenesis, suggesting that minocycline supplementation might be a potential strategy for improving ASD symptoms.
Insights
Minocycline treatment improved autism spectrum disorder (ASD)-like behaviors in mice by reducing neuroinflammation and enhancing neurogenesis. This suggests minocycline may be a potential therapeutic strategy for ASD.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with limited treatment options.
- Neuroinflammation and altered neurogenesis are implicated in ASD pathogenesis.
- Minocycline, an antibiotic with anti-inflammatory and neuroprotective properties, warrants investigation for ASD treatment.
Purpose of the Study:
- To investigate the efficacy of minocycline in ameliorating ASD-like behaviors in a BTBR mouse model.
- To explore the underlying mechanisms, including microglial activation, neuroinflammation, and neurogenesis.
Main Methods:
- Administration of minocycline to BTBR mice, a validated mouse model for ASD.
- Behavioral assessments to evaluate sociability and repetitive behaviors.
- Histological and molecular analyses of hippocampal tissue to assess neurogenesis and microglial activation.
Main Results:
- Minocycline administration significantly rescued sociability deficits and repetitive behaviors in BTBR mice.
- Treatment with minocycline enhanced hippocampal neurogenesis in BTBR mice.
- Minocycline inhibited microglial activation and Erk1/2 phosphorylation in the hippocampus of BTBR mice.
Conclusions:
- Minocycline effectively alleviates ASD-like behaviors in BTBR mice.
- The therapeutic effects are associated with reduced neuroinflammation and improved neurogenesis.
- Minocycline shows promise as a potential therapeutic agent for managing ASD symptoms.
